The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective

The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective

The emergence of immunotherapy, particularly programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) produced profound transformations for treating non-small cell lung cancer (NSCLC). Nevertheless, not all NSCLC patients can benefit from immunotherapy in clinical practice. In addit...

Full description

Bibliographic Details
Main Authors: Shuai Liang, Hanyu Wang, Haixia Tian, Zhicheng Xu, Min Wu, Dong Hua, Chengming Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Immunology
Subjects:
non-small cell lung cancer (NSCLC)
immunotherapy
prognostic biological markers
anti-PD-(L)1
review
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249980/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249980/full

Similar Items